Cc-5013 (Lenalidomide) (Capsules)


Combined with:

Dexamethasone Tab

Indications and Reactions:

Role Indications Reactions
Primary
Multiple Myeloma 79.2%
Myelodysplastic Syndrome 5.3%
5Q-syndrome 2.9%
Chronic Lymphocytic Leukaemia 2.8%
Non-hodgkin's Lymphoma 2.6%
Drug Use For Unknown Indication 2.0%
Myeloma Recurrence 1.1%
Complex Regional Pain Syndrome 0.5%
Lymphoma 0.5%
Anaemia 0.4%
B-cell Lymphoma Refractory 0.4%
Diffuse Large B-cell Lymphoma 0.4%
Hypertension 0.3%
Myelofibrosis 0.3%
Neoplasm 0.3%
Gastritis 0.2%
Pulmonary Embolism 0.2%
Amyloidosis 0.2%
B-cell Lymphoma 0.2%
Back Pain 0.2%
Thrombocytopenia 18.2%
White Blood Cell Count Decreased 10.7%
Renal Failure 7.5%
Death 7.2%
Sepsis 5.7%
Tumour Lysis Syndrome 5.7%
Multiple Myeloma 4.5%
Pulmonary Embolism 4.0%
Vomiting 4.0%
Pneumonia 3.7%
Somnolence 3.7%
Pyrexia 3.5%
Weight Decreased 3.5%
Septic Shock 3.2%
Respiratory Failure 3.0%
Urinary Tract Infection 2.7%
Renal Failure Acute 2.5%
Platelet Count Decreased 2.2%
Renal Impairment 2.2%
Tumour Flare 2.2%
Secondary
Multiple Myeloma 73.3%
5Q-syndrome 13.3%
Drug Use For Unknown Indication 6.7%
Glioblastoma 6.7%
Breast Cancer Stage I 14.3%
Drug Ineffective 14.3%
Osteoarthritis 14.3%
Septic Shock 14.3%
Staphylococcal Infection 14.3%
Urosepsis 14.3%
White Blood Cell Count Decreased 14.3%

Drug Data